“My body just feels like a magnet for cancer.” — Lisa Geller, an immunotherapy super-responder, on life before remission.
“That is a really important paradigm shift that could help a lot of people avoid overtreatment of prostate cancer and help a lot of physicians get a lot more confidence about their diagnoses.” — Michael Ahdoot, MD, NCI Urologic Oncology Branch, commenting on a study showing combined biopsy is more accurate than either MRI- or TRUS-guided biopsy.
“Nothing any of us is going to do will make more healthcare workers to fight this battle, so they get priority.” — Ken Cuccinelli, currently performing the duties of deputy secretary at the Department of Homeland Security, on how healthcare workers are a “limited resource” on the COVID-19 front.
“The risk of off-target activity like that is very low, but we can’t say it’s zero.” — Eric Pierce, MD, PhD, of Harvard Medical School in Boston, on the chance for “off-site targeting” during a CRISPR gene-editing procedure in humans.
“I leave it to your readership to decide whether further investigation of these robotic procedures should be pursued when the expected outcome is likely to be the same.” — A. James Moser, MD, of the Pancreas and Liver Institute at Beth Israel Deaconess Medical Center in Boston, discussing any potential advantages of a robot-assisted Whipple procedure.
“Physicians are on the front-line of this crisis, but may not be equipped to recognize prescription drug misuse.” — Jeffrey Gudin, MD, of Rutgers New Jersey Medical School in Newark, about the struggles doctors face treating chronic pain patients.
“The search is to find out whether the relationship is across the board — whether it’s all opiates, all doses, all formulations — or whether we can identify a high-risk group.” — Andrea Rubinstein, MD, of Kaiser Permanente in Santa Rosa, California, about hypogonadism in men on long-term opioids.